Azidothymidine in the Treatment of AIDS

Pamela jo Harris, Cesar A. Caceres, Barbara Bell, A. Ganser, J. Greher, B. Völkers, S. Staszewski, D. Hoelzer, Douglas D. Richman, Margaret A. Fischl, Sandra Nusinoff-Lehrman, David W. Barry

Research output: Contribution to journalLetterpeer-review

26 Scopus citations


To the Editor: Richman et al., in reviewing the experience of the AZT Collaborative Working Group on the toxicity of azidothymidine (zidovudine [Retrovir], or AZT) in the July 23 issue,* reported that 45 percent of patients receiving AZT had some hematologic toxic effects. They also reported that most patients receiving AZT had at least one clinical symptom, such as headache, asthenia, diarrhea, abdominal pain, or fever, but they did not report that any patients had neurologic symptoms. We have recently seen a 43-year-old male patient, positive for antibodies to the human immunodeficiency virus (HIV), who had grand mal epileptic seizures.

Original languageEnglish (US)
Pages (from-to)250-251
Number of pages2
JournalNew England Journal of Medicine
Issue number4
StatePublished - Jan 28 1988

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Azidothymidine in the Treatment of AIDS'. Together they form a unique fingerprint.

Cite this